A New Frontier in Precision Oncology Prostate cancer continues to be one of the most prevalent cancers in men worldwide, […]
Visano Theranostics has been selected for JumpStart's Trailblazer HealthTech Accelerator, a prestigious 3-month program that provides healthcare startups with expert mentorship, regulatory guidance, and access to up to $275,000 in development services.
The Visano Solution
Enhancing The Future Of Ultrasound Imaging.
The Visano Solution
We are developing a new ultrasound contrast agent called nanobubble (NB) to help improve the detection and treatment of prostate cancer. These nanobubbles specifically target PSMA, a marker found in high amounts on prostate cancer cells, which allows for precise detection and treatment that focuses only on the cancer, leaving healthy cells unharmed.
Nanobubbles can be used in several ways:
They can help clearly identify tumors during standard prostate needle biopsy using transrectal ultrasound.
They can guide focal therapies like high-intensity focused ultrasound (HIFU) to precisely target and destroy tumors.
They can be used to evaluate the success of ablation therapies.
Using a stronger ultrasound pulse, nanobubbles can also deliver targeted therapy (called TNT) that bursts the bubbles and destroys cancer cells directly.
Overall, nanobubbles can enhance the capabilities of current ultrasound technology, making prostate cancer diagnosis and treatment more accurate, less invasive, and fewer side effects.
Meet Our Team
James P. Basilion, Ph.D.
Inventor, Co-founder
Professor of Radiology & BME, CWRU
30+ years of experience in molecular oncology, translational tech
James P. Basilion, Ph.D.
Inventor, Co-founder
In addition to his primary roles, Dr. Basilion is actively engaged with various professional organizations, including the World Molecular Imaging Society and the Radiological Society of North America, where he continues to contribute to the advancement of medical imaging and cancer research. He is a Senior Member of the National Academy of Inventors, a Fellow of the World Molecular Imaging Society, and a Fellow of the National Foundation for Cancer Research.
Agata A. Exner, Ph.D.
Inventor, Co-founder
Director of the CWRU Center for Imaging Research and a leading expert in molecular imaging and theranostics.
Agata A. Exner, Ph.D.
Inventor, Co-founder
Michael J. Haag, MS, MBA
Co-founder, Chief Executive Officer
Expert in tech transfer and startups with 25+ years experience, formerly at CWRU, now leading innovation through TherExel LLC.
Michael J. Haag, MS, MBA
Co-founder, Chief Executive Officer
During his tenure at CWRU, Michael led the re-establishment of Case Technology Ventures (CTV), later rebranded as The Spartan Fund, which he served as its Managing Director. The Spartan Fund became a vital pre-seed, evergreen venture fund designed to support early-stage, high-risk technologies from the university. Under Michael’s leadership, the Spartan Fund Catalyst Program, which provided $5,000 in consulting services to startups going through the diligence process was established. His work contributed to the growth and success of CWRU's entrepreneurial ecosystem, with over 80 start-ups launched, 10 of which were acquired and three exited through IPOs, collectively representing an exit value of more than $325 million.
In addition to his venture creation efforts, Michael secured approximately $3.5 million in commercialization grants as Principal Investigator and played an integral role in managing translational research programs, which invested over $2 million annually. His leadership in technology transfer resulted in over $40 million in total revenue for CWRU, including negotiating four of the largest up-front payments in the university’s history.
In 2023, Michael founded TherExel LLC, a technology commercialization consulting firm. This move reflects his ongoing passion for start-up creation and venture development. Throughout his career, Michael has cultivated a vast network of industry connections, including investors, entrepreneurs, and key stakeholders, which he leverages to drive innovation and partnerships. His dedication to translational research and venture creation has made him a highly respected figure in both the academic and business communities.
Michael holds an M.S. in biology from CWRU, an M.B.A. from the University of Phoenix, and a B.S. in Biology and Chemistry from John Carroll University. He is a member of the Licensing Executives Society and the Association of University Technology Managers.
About Our Technologies
Explore how nanobubble innovation is driving breakthroughs in cancer diagnosis and precision therapy.
Why Nanobubbles?
VISANO: Revolutionizing Cancer Diagnosis and Treatment with Nanobubbles In the ever-evolving fight against cancer, innovation is crucial. Traditional diagnostic tools.
Lead Application.
Revolutionizing Prostate Cancer Diagnosis and Treatment with Nanobubble Contrast Agents Prostate cancer remains one of the most commonly diagnosed cancers.
Visano’s Solution: Targeted Nanobubble Therapy.
A New Frontier in Precision Oncology Prostate cancer continues to be one of the most prevalent cancers in men worldwide.
Our Publications
Explore peer-reviewed studies and scientific breakthroughs highlighting the cutting-edge role of nanobubbles in diagnostics, cancer imaging, and more.
Nanobubble Contrast Enhanced Ultrasound Imaging: A Review.
Contrast; microbubbles; nanobubbles; nonlinear; ultrasound.
Ultrasound-mediated drug-free theranostics for treatment of prostate cancer.
Contrast enhanced ultrasound; Nanobubbles; PC-3 Cells; Prostate-specific membrane antigen (PSMA); Ultrasound-mediated therapy.
PSMA-Targeted Nanobubbles Show Enhanced Stability via Intracellular Entrapment.
Cellular internalization; nanobubble ultrasound contrast agents; prostate cancer; prostate-specific membrane antigen (PSMA); ultrasound molecular imaging.
PSMA-Targeted Nanobubbles for Prostate Cancer Imaging.
PSMA-targeted nanobubbles improve ultrasound imaging of prostate cancer by enhancing tumor retention and contrast, offering potential for better diagnosis and targeted biopsy.
Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles.
Nanobubbles; Prostate cancer; Prostate specific membrane antigen; Ultrasound eco site; Ultrasound molecular imaging.
Our Publications
Explore peer-reviewed studies and scientific breakthroughs highlighting the cutting-edge role of nanobubbles in diagnostics, cancer imaging, and more.
Real time ultrasound molecular imaging of prostate cancer with PSMA-targeted nanobubbles
Nanobubbles; Prostate cancer; Prostate specific membrane antigen; Ultrasound contrast agents; Ultrasound molecular imaging.
PSMA-Targeted Nanobubbles for Prostate Cancer Imaging
PSMA-targeted nanobubbles improve ultrasound imaging of prostate cancer by enhancing tumor retention and contrast, offering potential for better diagnosis and targeted biopsy.
PSMA-Targeted Nanobubbles Show Enhanced Stability via Intracellular Entrapment
Cellular internalization; nanobubble ultrasound contrast agents; prostate cancer; prostate-specific membrane antigen (PSMA); ultrasound molecular imaging.
Ultrasound-mediated drug-free theranostics for treatment of prostate cancer
Contrast enhanced ultrasound; Nanobubbles; PC-3 Cells; Prostate-specific membrane antigen (PSMA); Ultrasound-mediated therapy.
Nanobubble Contrast Enhanced Ultrasound Imaging: A Review
Contrast; microbubbles; nanobubbles; nonlinear; ultrasound.
Latest News & Blogs
Discover recent breakthroughs, trends, and real-world applications of nanobubble technology across industries.
Revolutionizing Prostate Cancer Diagnosis and Treatment with Nanobubble Contrast Agents Prostate cancer remains one of the most commonly diagnosed cancers […]
VISANO: Revolutionizing Cancer Diagnosis and Treatment with Nanobubbles In the ever-evolving fight against cancer, innovation is crucial. Traditional diagnostic tools […]